Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Precision Biosciences (DTIL)
:DTIL
RESEARCH TOOLSreports
Holding DTIL?
Track your performance easily
DTIL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.61 - $19.43
Previous CloseN/A
Volume55.33K
Average Volume (3M)834.39K
Market Cap
$44.98M
Enterprise Value-$5.60M
Total Cash (Recent Filing)$62.80M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)112.3
Beta2.11
Next Earnings
Mar 18, 2025EPS Estimate
-2.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding7,891,771
10 Day Avg. Volume2,222,101
30 Day Avg. Volume834,393
Standard Deviation0.25
R-Squared0.10
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.58
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.12
Enterprise Value/Revenue-0.07
Enterprise Value/Gross Profit-0.11
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$41.33Price Target Upside620.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Precision BioSciences News
PremiumCompany Announcements
Precision BioSciences Advances Gene Editing Trials GloballyBulls Say, Bears Say
Bulls Say
Clinical SuccessFirst ever in vivo gene editing clinical success validates Precision's 2023 decision to pivot its ARCUS platform to in vivo gene editing.
Platform ValidationThe ARCUS technology used by Precision Bio now has clinical validation of in vivo delivery and gene insertion, marking an important milestone for the company.
Therapeutic PotentialThe initial ECUR-506 data provide the first ever clinical evidence with any in vivo gene editing and gene insertion modality, supporting the therapeutic potential of Precision's ARCUS platform.
Bears Say
Clinical RisksNew safety concerns with in vivo gene editing and failure to execute in vivo editing in patients.
Partnership RisksTermination of existing partnerships on gene editing programs and negative data from peers resulting in drug class risks.
Regulatory And Business Development RisksDelays in IND submissions and competitive pressure from peer gene editing companies.
---
Ownership Overview
2.46% Insiders
4.49% Mutual Funds
0.40% Other Institutional Investors
89.38% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DTIL FAQ
What was Precision Biosciences’s price range in the past 12 months?
Precision Biosciences lowest stock price was $3.61 and its highest was $19.43 in the past 12 months.
What is Precision Biosciences’s market cap?
Precision Biosciences’s market cap is $44.98M.
When is Precision Biosciences’s upcoming earnings report date?
Precision Biosciences’s upcoming earnings report date is Mar 18, 2025 which is in 63 days.
How were Precision Biosciences’s earnings last quarter?
Precision Biosciences released its earnings results on Nov 04, 2024. The company reported -$2.25 earnings per share for the quarter, missing the consensus estimate of -$2.136 by -$0.114.
Is Precision Biosciences overvalued?
According to Wall Street analysts Precision Biosciences’s price is currently Undervalued.
Does Precision Biosciences pay dividends?
Precision Biosciences does not currently pay dividends.
What is Precision Biosciences’s EPS estimate?
Precision Biosciences’s EPS estimate is -2.25.
How many shares outstanding does Precision Biosciences have?
Precision Biosciences has 7,891,771 shares outstanding.
What happened to Precision Biosciences’s price movement after its last earnings report?
Precision Biosciences reported an EPS of -$2.25 in its last earnings report, missing expectations of -$2.136. Following the earnings report the stock price went down -8.093%.
Which hedge fund is a major shareholder of Precision Biosciences?
Currently, no hedge funds are holding shares in DTIL
---
Precision BioSciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.33 (620.03% Upside)
$41.33 (620.03% Upside)
Insider Transactions
Bought Shares
Worth $81.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.51%
12-Months-Change
Fundamentals
Return on Equity
24.44%
Trailing 12-Months
Asset Growth
-6.75%
Trailing 12-Months
Company Description
Precision Biosciences
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
---
DTIL Stock 12 Month Forecast
Average Price Target
$41.33
▲(620.03% Upside)
Technical Analysis
Arcturus Therapeutics
―
Adaptimmune Therapeutics
―
Caribou Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering DTIL
1 Year
1 Year Success Rate
1/21 ratings generated profit
1 Year Average Return
-55.07%
assigned a buy rating 5 days ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 4.76% of your transactions generating a profit, with an average return of -55.07% per trade.
---